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Abstract
Background: Intellectual disability (ID) affects 2–3% of the population and may occur with or without multiple congenital
anomalies (MCA) or other medical conditions. Established genetic syndromes and visible chromosome abnormalities
account for a substantial percentage of ID diagnoses, although for ,50% the molecular etiology is unknown. Individuals
with features suggestive of various syndromes but lacking their associated genetic anomalies pose a formidable clinical
challenge. With the advent of microarray techniques, submicroscopic genome alterations not associated with known
syndromes are emerging as a significant cause of ID and MCA.
Methodology/Principal Findings: High-density SNP microarrays were used to determine genome wide copy number in 42
individuals: 7 with confirmed alterations in the WS region but atypical clinical phenotypes, 31 with ID and/or MCA, and 4
controls. One individual from the first group had the most telomeric gene in the WS critical region deleted along with 2 Mb
of flanking sequence. A second person had the classic WS deletion and a rearrangement on chromosome 5p within the Cri
du Chat syndrome (OMIM:123450) region. Six individuals from the ID/MCA group had large rearrangements (3 deletions, 3
duplications), one of whom had a large inversion associated with a deletion that was not detected by the SNP arrays.
Conclusions/Significance: Combining SNP microarray analyses and qPCR allowed us to clone and sequence 21 deletion
breakpoints in individuals with atypical deletions in the WS region and/or ID or MCA. Comparison of these breakpoints to
databases of genomic variation revealed that 52% occurred in regions harboring structural variants in the general
population. For two probands the genomic alterations were flanked by segmental duplications, which frequently mediate
recurrent genome rearrangements; these may represent new genomic disorders. While SNP arrays and related technologies
can identify potentially pathogenic deletions and duplications, obtaining sequence information from the breakpoints
frequently provides additional information.
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Introduction
Many genetic diseases and disorders are caused by alteration
of gene dosage due to duplication or deletion of large genomic
regions [1]. More benign copy number variants (CNVs) are
common, although they may contribute to normal individual
variation and the occurrence of complex diseases in the general
population [2,3]. Many deletion/duplication abnormalities are
known to cause intellectual disability (ID) and/or multiple
congenital anomalies (MCA) as part of well-characterized
genetic syndromes. While ID affects ,2–3% of the population
[4] and is the most common serious disability in children and
young adults [5], an accurate diagnosis is possible in fewer than
50% of cases [4–6]. Visible chromosome aberrations, which
constitute the majority of definitive diagnoses, are found in
approximately 28% of individuals with ID [7]. Of the re-
maining cases, half are estimated to have an underlying genetic
cause [5].
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(WS, OMIM:194050) [8], Prader-Willi/Angelman syndromes [9]
Smith-Magenis syndrome [10], and Charcot-Marie-Tooth disease
type 1A/hereditary neuropathy with liability to pressure palsies
[11,12], are caused by submicroscopic chromosome abnormalities
with recurring breakpoints. Clinical diagnoses are relatively
straightforward for these syndromes because there are well-defined
suites of clinical features and it is possible to rapidly test for the
appropriate chromosome anomaly. Architectural features of the
genome, most commonly low copy repeats (LCRs, also known as
segmental duplications), are associated with deletion or duplication
boundaries in these disorders and have been causally implicated in
their characteristic genome rearrangements [1,13–15]. Intra-
chromosomal non-allelic homologous recombination (NAHR)
between directly oriented LCRs causes deletions or duplications,
while NAHR between inverted repeats leads to inversions [1].
With the advent of array comparative genomic hybridization
(aCGH) and microarray techniques it is now possible to examine
the genome of individuals with non-syndromic ID and MCA at
even higher resolution. Such studies have identified putatively
pathogenic genome rearrangements in 10–25% of otherwise
undiagnosable ID cases [16–22]. Identification of affected genes
in these cases may suggest targeted genetic tests in other probands
with similar phenotypes.
The WS clinical phenotype includes elastin arteriopathy,
developmental delay (DD) and/or ID, and a recognizable pattern
of dysmorphic facial features [23]. Over the past several years we
have studied the relation between phenotype and genotype in
individuals with WS, which is characterized by a deletion of
7q11.23. During this time numerous individuals with an initial
diagnosis of WS were referred to us whom on subsequent
cytogenetic analyses were found not to have the typical 7q23.11
deletion. These individuals, who had ID and/or MCA, pose
difficult challenges with respect to treatments and recurrence risk.
In an attempt to ascertain the cause of the phenotypes in 31 such
individuals we used SNP microarrays to determine genome wide
copy number. We report that 6/31 individuals had large genome
rearrangements, either deletions or duplications, which may be
responsible for their clinical phenotypes. Two in particular were
the result of alteration in regions flanked by LCRs, which may
represent regions of genomic instability.
Materials and Methods
Participants
All participants were part of a 14-year study of genotype-
phenotype relations in WS. Most of the probands in this report, 31
individuals with unidentified ID and or MCA, were referred to us
with a clinical diagnosis of WS but subsequently tested negative for
the expected 7q11.23 deletion using fluorescent in situ hybridiza-
tion (FISH). In addition, samples from seven probands with
cytogenetically confirmed chromosome 7 alterations and four
individuals from the general population were used to validate our
methods and ensure our analysis strategy could identify the
expected alterations. Familial relationships were confirmed using
the GenePrint GammaSTR kit (Promega, Madison, WI). All
participants and/or their parents/guardians signed informed
consent forms under protocols approved by the Institutional
Review Boards of the University of Nevada School of Medicine
and/or the University of Louisville.
Cytogenetics
High-resolution cytogenetic analyses used standard methods
including thymidine synchronization of the cultured cells and
addition of ethidium bromide during metaphase harvest. FISH
analyses were performed as described previously [24]. Probes were
obtained through commercial sources (MYCN region, Vysis/
Abbott, Des Plaines, IL) or generated from purified BACs.
Observation was performed with a Zeiss Axioscop (Go ¨ttingen,
Germany) and documented on a Metasystems (Altlussheim,
Germany) imaging system. Image levels were adjusted in Photo-
shop CS2 (Adobe, San Jose, CA).
SNP copy number determination
DNA was isolated from cultured lymphoblastoid cell lines
(LBLs), fibroblasts, or peripheral blood lymphocytes (PBLs). DNA
from PBLs was used whenever possible to exclude the possibility of
cell line artifacts. RNA was isolated from LBLs using a Ribopure
RNA isolation kit (Ambion, Austin, TX), and cDNA was
synthesized using Superscript III reverse transcriptase and random
primers (Invitrogen, Carlsbad, CA).
Genomewide SNP copy number was determined using the
Affymetrix Human Mapping 500K SNP Array Set (Affymetrix,
Santa Clara, CA) consisting of 250K StyI and NspI subarrays
containing probes for 238,304 and 262,264 SNPs, respectively.
DNA was prepared for array analyses, and arrays were hybridized,
washed, stained, and scanned following the manufacturer’s
protocol (Affymetrix, Santa Clara, CA). Genotypes were deter-
mined by Affymetrix GTYPE 4.0 software using the DM
algorithm. CEL files were normalized and modeled in dChip
using invariant set normalization and a perfect match/mismatch
difference model [25]. Subarrays were normalized and modeled
separately and subsequently combined for analyses. Copy number
was inferred using median smoothing with a 7 SNP window and
10% trimming including all samples as references. Loss of
heterozygosity was calculated by hidden Markov model consider-
ing haplotype with all samples considered to be references.
MIAME compliant array data from this study have been uploaded
to the Gene Expression Omnibus (GEO) database. Relevant data
for the probands discussed in this manuscript will be submitted to
the DECIPHER database.
CNVs were identified by statistical analysis of inferred copy
number using Partek Genomics Suite 6.3 (Partek, St. Louis, MO).
The significance of SNP copy number changes was determined
using a 50 kb window and copy number thresholds of 1.5 and 2.4
for deletions and duplications, respectively. CNVs were detected
using a minimum region size of 50 kb and p-value cutoff of 0.01.
These parameters were selected to minimize false-positive results
and were not suitable for the identification of small variants.
Statistically identified regions were visualized in dChip to remove
artifacts due to low SNP density and edited using raw copy
number to more precisely refine endpoints. The boundaries of
potentially pathogenic CNVs were confirmed by qPCR and
cloned when possible.
Determining whether CNVs are likely to be pathogenic versus
benign is one of the greatest difficulties currently facing clinical
geneticists. We considered CNVs to be putatively benign if they
are present as normal polymorphisms in the UCSC Genome
Browser’s structural variation track [26] and/or the Database of
Genomic Variants [27], and/or were present in at least one of our
general-population control samples. Novel CNVs that occurred in
multiple probands with different clinical presentations were also
considered to be normal polymorphisms. We chose to consider
CNVs potentially pathogenic if they met one or more of the
following criteria: (1) affected at least one gene whose haploinsuf-
ficiency or mutation is known to cause an abnormal phenotype
based on the database of Online Mendelian Inheritance in Man
[28]; (2) affected at least five Reference Sequence (RefSeq) genes
Detecting Genomic Disorders
PLoS ONE | www.plosone.org 2 August 2010 | Volume 5 | Issue 8 | e12349whose copy numbers are not known to vary in the general
population; (3) intersected a region associated with a known
genetic disorder or Database of Chromosomal Imbalance and
Phenotype in Humans using Ensembl Resources (DECIPHER)
[29] feature. RefSeq genes are those annotated as part of the effort
to provide a comprehensive list of all genes for all organisms
(http://www.ncbi.nlm.nih.gov/RefSeq/index.html). In one case
(9152) these criteria conflicted with a report of a CNV in the
general population. This discrepancy was resolved by consider-
ation of CNV credibility versus evidence for pathogenicity (see
Discussion). Genes of unknown function that are strongly
expressed in fetal and/or adult neural and/or cardiac tissues were
considered potential candidates for developmental disorders with
phenotypic features overlapping WS. Whenever possible, putative
abnormalities were determined to be de novo by SNP array or
qPCR.
Cloning of deletion breakpoints
Microarray analyses allowed us to identify the location of
molecular breakpoints to varying extents, which were largely
determined by the SNP density on the arrays. In regions where the
SNP density was low we designed qPCRs across the deleted region
to narrow the interval to ,40 kilobases (kb). To clone the deletion
breakpoints we used one of several strategies. First, we designed
PCR primers at 3–4 kb intervals between the nearest deleted and
non-deleted region, on both sides of the deletion (Figure S1). PCR
reactions using all combinations of forward and reverse primers
then were analyzed. If any primer pair yielded PCR products, they
were cloned and sequenced. If this strategy failed, we used either
adaptor ligation based PCR walking [30] or inverse PCR to
amplify junction fragments. For all identified junction fragments,
PCRs were designed to confirm the junction position in genomic
DNA. The sequence of the primers used and 100 bp of flanking
DNA for each breakpoint are given in Table S1.
PCRs (20 ml) contained ,100 ng of genomic DNA and
AccuPrime Taq DNA Polymerase High Fidelity in buffer II
(Invitrogen, Carlsbad, CA). DNA fragments were cloned into
pCR-4-TOPO (Invitrogen Inc., Carlsbad, CA) and sequenced
using the BigDye Terminator v3.1 kit (Applied Biosystems, Foster
City, CA) on an ABI 3130xl Genetic Analyzer (Applied
Biosystems, Foster City, CA). Sequences were mapped to physical
positions on the February 2009 Human genome assembly, using
the UCSC BLAST-Like Alignment Tool [31]. The BLAST 2
sequences program [32] was used to evaluate the regions flanking
breakpoints for sequence similarity. Genome architecture at the
breakpoints was examined using the segmental duplication [15]
and RepeatMasker [33] tracks of the UCSC genome browser [26].
Quantitative PCR analyses were done using either TaqMan
assays or Power SYBR Green PCR Master Mix (Applied
Biosystems, Foster City, CA) and standard primers (Table S2)
on an ABI 7900HT Real-Time PCR System (Applied Biosystems,
Foster City, CA). All reactions (10 ml) contained 5 ng of DNA and
were analyzed using conditions recommended by the manufac-
turer. Copy number using triplicate reactions was calculated by
the instrument software using the DDCT method, with parental
samples used as references whenever possible. Relative values for
gene expression were determined using TaqMan assays for GTF2I
(Hs00263393_m1) relative to 18S RNA (Hs01073657_m1) as
recommended by the manufacturer (Applied Biosystems, Foster
City, CA).
Web Resources
BLAST 2 sequences, http://www.ncbi.nlm.nih.gov/blast/
bl2seq/wblast2.cgi; Database of Genomic Variants, http://
projects.tcag.ca/variation/; dChip, http://www.dchip.org; DECI-
PHER, http://decipher.sanger.ac.uk/; UCSC BLAT, http://
genome.ucsc.edu/cgi-bin/hgBlat; UCSC Genome Browser, http://
genome.ucsc.edu/cgi-bin/hgGateway. Reference Sequence (Re-
fSeq), http://www.ncbi.nlm.nih.gov/RefSeq/index.html.
Results
Genome copy number was determined using 500K SNP
microarrays on 42 individuals. The analyzed samples fell into
three groups. The first group contained 7 probands who had
previously been identified with chromosome 7q11.23 alterations
but whose clinical phenotypes suggested either deletion lengths not
typical for WS or the possibility of additional genetic lesions. The
second group consisted of 31 individuals who had ID/DD and/or
MCA and had been previously diagnosed with WS but who did
not have the characteristic 7q11.23 deletion. The third group
consisted of 4 control individuals with normal phenotypes and
karyotypes. Tables S3 and S4 summarize the molecular and
clinical findings, respectively, of the individuals with genomic
alterations described in detail below.
Analyses of probands with chromosome 7 alterations
A major focus of our research effort has been to correlate
phenotype and genotype in individuals with WS or other
chromosome 7q11.23 alterations. Seven probands with cytoge-
netically confirmed chromosome 7 alterations were analyzed by
microarrays: five probands with 7q11 deletions and two
probands with 7q11 duplications. Two probands with WS and
one proband with a duplication showed the expected deletion or
duplication of the WS critical region, respectively, and are not
discussed further. Of the remaining 4 probands, 3 had atypical
deletions and one had a 7q11 duplication and a deletion on
chromosome 1.
Three of the probands with chromosome 7 deletions (8399,
9061, 9101) provide new insights into the nature of genome
rearrangements and highlight the power of this approach to refine
and discover new potentially pathogenic changes at the genome
level. In all three cases we were able to clone the deletion
breakpoints providing accurate information about which genes
were deleted. Figure 1 shows the alignment of chromosome 7
ideograms indicating the extent of the deletions in these three
individuals relative to the typical WS deletion. Below each
schematic of the deletion is shown the sequence of the deletion
junction.
Proband 8399 has WS and additional features including severe
ID and a seizure disorder. The array analyses and subsequent
cloning of the breakpoint showed this individual has a 10.8 Mb
deletion (Figure 1A) which begins 1.2 Mb centromeric to and ends
3.5 Mb telomeric to the typical WS deletion. In total, this deletion
removes 91 RefSeq genes (Figure S2).
Proband 9061 and four additional family members have been
described previously (pedigree K3804 in ref. 24) and have an
atypically small deletion within the WS region. They have normal
intelligence but have deficits in visuospatial construction, which is
characteristic of individuals with WS [34]. The SNP arrays refined
the deletion end points sufficiently to allow us to clone a 4.2 kb
fragment containing the deletion junction (Figure 1B). Sequence
alignments indicated the deletion was 503 kb and includes 13
RefSeq genes (Figure S2). The deletion begins in MLXIPL and
extends to and includes most of LIMK1. Haploinsufficiency of
LIMK1 is thought to be critical to the visuospatial construction
deficits seen in individuals with WS and therefore is consistent with
the phenotype in this proband.
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supravalvar aortic stenosis and on cytogenetic analysis was found
both to have the WS region deleted and also a translocation,
t(7;11)(q21.1;p14), unrelated to the deletion and telomeric to the WS
region. FISH analyses showed that the deletion involving the WS
region extended further in the telomeric direction than does the
typical WS deletion. Array analyses and cloning of the breakpoint
indicated the deletion was approximately 4.4 Mb (Figure 1C) and
affects 71 RefSeq genes (Figure S2). From the array analyses there
was no indication that thereweredeletionsorduplications associated
with the translocation breakpoints t(7;11)(q21.1;p14) (data not
shown). However, another large deletion of 7.38 Mb was detected
on chromosome 5 that impacted 13 RefSeq genes (Figures 2A and
S2). The reason this deletion was not detected in the original
karyotypingisunclearbut likelyrelates tothe factthat italsoinvolves
a large inversion. We cloned the chromosome 5 breakpoint and the
most parsimonious conclusion was that the deletion was also
associatedwithaninversion,shownschematicallyinFigure2B.PCR
analyses of the predicted junction fragments supported this
conclusion and showed the rearrangement occurred de novo in the
proband. Finally, we used metaphase FISH with three BAC clones
that based on the sequence predictions should be diagnostic of the
inversion. These analysesshow that one ofthetwo chromosomes has
the predicted inversion (Figure 2C). Analyses of the inversion
Figure 1. Breakpoint identification in individuals with deletions in the WS region and atypical phenotypes. Chromosome 7 ideograms
showing the region of interest, including the typical WS deletion (yellow boxes) relevant to rearrangements in probands 8399, 9061, and 9101. The
LCR and CNV tracks show the location of these features. The copy number track for each individual shows the copy number data from the arrays
(black dots), analyzed as described in Methods. The red box on the ideogram represents the extent of the deletion. The sequence tracks show the
sequence of the junction fragment aligned with the same region from the non-deleted chromosome. The sequence highlighted in green for
probands 9061 and 9101 is present at both breakpoints so the actual break cannot be known. The gel images to the right show the validation of the
junctions by PCR amplification of the junction fragment from genomic DNA. (A). Proband 8399 has a 10.8 Mb deletion that includes the entire WS
typical region and includes 91 genes. The parents of 8399 were lost to follow up but the junction fragment was absent from two control samples. (B)
Proband 9061 has a deletion of 503 kb affecting 13 genes, which includes only part of the WS critical region. The gel image to the right shows the
junction fragment was inherited from her mother and was absent from an unaffected relative. (C) Proband 9101 has a 4.4 Mb deletion affecting 71
genes including the entire WS critical region. Chromosome ideogram is the same as that for 9061. The gel image shows this was a de novo deletion in
the proband because the junction fragment was absent in both parents. A detailed list of affected genes in these three probands is provided in
Figure S2.
doi:10.1371/journal.pone.0012349.g001
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centromeric to the deletion, also was disrupted. The affected genes
on chromosome 5 are all within the Cri du Chat syndrome region
and likely contribute to the child’s complex phenotype.
The fourth proband studied (9164) in this group was known to
have a duplication in the WS region and initially was used as a
control. However, we discovered a 1.46 Mb de novo deletion on
1q21.1 in this proband (Figure S2). This rearrangement has been
previously reported as a genomic disorder with variable pene-
trance and has been found in both affected and unaffected
individuals [35]. The clinical features in this proband are
consistent with those of other individuals who have 7q11.23
duplications [36–38], indicating the deletion at 1q21.1 in this
individual may not have any phenotypic effect.
High frequency of genome copy number alterations in
individuals with MCA and/or ID or DD
Over the past several years we have had many individuals
referred to our study who carried a diagnosis of WS but who on
subsequent clinical evaluation did not have WS. In general these
individuals had non-syndromic MCA, and/or ID and/or DD. We
used genome wide copy number analyses to screen 31 of these
probands for potential genome abnormalities. Potentially patho-
genic rearrangements were discovered in 6 probands. In these cases
the alterations were confirmed using qPCR along with cloning
breakpoints when possible. The location, size of alteration (deletion
or duplication), number of RefSeq genes affected, and any features
of interest at the breakpoints are given in Table S3. Three probands
had deletions (including one mosaic deletion) and three had
duplications that we hypothesize are responsible for their pheno-
types, confirmation of which will require identification of additional
individuals with similar alterations and phenotypes. The specific
rearrangements for each of the 6 probands are described briefly
below and in Table S3 part B. A clinical summary of each proband
is given in Table S4, part B. In addition, our analyses identified 117
other regions of copy number variation (Table S5). Many of these
have been previously reported in the general population, and none
satisfy our criteria for potential pathogenicity.
Figure 2. Determination of a complex rearrangement on chromosome 5p15.2-5p14.3 required sequencing deletion breakpoints.
(A) Ideogram of chromosome 5 showing the 5p15.2-5p14.3 deletion present in proband 9101. The copy number plot was derived from our
microarray (black dots) and qPCR (Xs) results. The green arrowhead indicates an inherited CNV at the telomeric deletion breakpoint. Black and gray
boxes depict regions of normal copy number, the red box indicates the extent of the deletion, and the gray box shows the inverted region. The
sequence tracks show junction fragments along with genomic positions and orientations of flanking sequences. Eight base pairs of 5p14.2 sequence
present at both breakpoints are highlighted in green. (B) Schematic of deletion and inversion including relative locations of PCR primers and FISH
probes on reference and affected chromosomes 5. Telomeric is to the left. The gel image on the right shows amplification of the junction fragments
present at the deletion/inversion breakpoints. The absence from both parents indicates this rearrangement occurred de novo.( C) Metaphase FISH
analyses of cells from proband 9101, using BAC probes RP11-91A5 (green), RP11-91E20 (red), and RP11-90G17 (yellow) confirming the presence of the
inverted region of chromosome 5p14.5 (white arrowhead).
doi:10.1371/journal.pone.0012349.g002
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He has a 2.57 Mb deletion on chromosome 5q15. Sequencing of
the breakpoint showed that 15 RefSeq genes were deleted
(Figures 3A and S3). The centromeric breakpoint was within the
C5ORRF21 gene and the telomeric breakpoint just centromeric of
PCSK1.
Proband 9152 has DD and mildly dysmorphic features. She has
a de novo 2.13 Mb deletion at 7q11.23, with the centromeric
breakpoint in the telomeric block of CNVs that give rise to WS
(Figures 3B and S3). We were particularly interested in this
deletion because of the possibility that GTF2I, which extends into
the telomeric CNVs flanking the WS critical region, might be
disrupted without other genes in the WS critical region being
affected. GTF2I is a transcription factor, haploinsufficiency of
which has been implicated in ID, visuospatial construction deficits,
and/or personality characteristics associated with WS [24,34,38].
To evaluate whether GTF2I was disrupted we first examined its
expression levels in LBLs from the proband, the proband’s
unaffected sibling, and seven unrelated individuals with known
deletions that included GTF2I. The expression level of GTF2I in
LBLs from proband 9152 was 49% of the sibling’s and similar to
that in the seven individuals with known deletions (data not
shown), suggesting GTF2I may be disrupted in proband 9152. The
SNP arrays we used had poor resolution in the CNVs that flank
the WS region. However, the arrays localized the telomeric
deletion breakpoint to within intron 6 of ZP3 (Figure 3B). We
hypothesized that if the deletion was in the GTF2I gene then a
GTF2I-ZP3 fusion transcript might be produced, which would
allow us to precisely define the centromeric breakpoint. We used
RT-PCR with primers in exon 2 of GTF2I and exon 7 of ZP3 and
amplified a 2.1 kb cDNA fragment from proband 9152. Sequence
analysis showed it to be derived from a fusion of exons 2–9 and
11–12 of GTF2I and exon 7 of ZP3. This predicts the centromeric
deletion breakpoint is within intron 12 of GTF2I, which is
embedded in the CNVs that mediate the typical WS deletion. The
fusion of GTF2I mRNA with ZP3 is out of frame and is predicted
to produce a truncated GTF2I protein that contains an additional
12 amino acids. This fragment of GTF2I contains the domain
involved in dimer formation and could potentially act as a
dominant negative, although its reduced expression level may
decrease the likelihood of this outcome. In addition to GTF2I and
ZP3, this child is haploinsufficient for 32 other RefSeq genes
(Figures 3B and S2).
One proband (8722), who was lost to follow-up, showed a SNP
copy number of ,1.5 for a 0.81 Mb region on chromosome
2p11.2 suggesting a mosaic deletion (Figures 4A and S3). To
Figure 3. Deletion breakpoints on chromosome 5 and 7 associated with ID/MCA. Chromosome features for the region of interest are
shown versus the physical position in Mb on the February 2009 human genome assembly. Red boxes on ideograms denote regions of detail. Gene
and LCR tracks were adapted from the UCSC Genome Browser. CNV tracks show type and position as reported in the general population: red, loss;
green, gain; blue, both. The copy number chart was derived from our SNP microarray (black dots) and qPCR (Xs) results. The red box on the copy
number plots indicates the deletion. Sequence tracks from top to bottom show the junction fragment and the sequences flanking the centromeric
and telomeric breakpoints. Regions of sequence identity at the breakpoints are highlighted in green. (A) Deletion of 2.57 Mb at 5q15 in proband
9239 that involves 15 genes. The gel image shows the presence of a PCR fragment amplified from the deletion junction in the proband but not in
control samples (parental samples were not available). (B) Deletion of 2.13 Mb at 7q11.23 in proband 9152 that involves 34 genes. Genes shown in
red are typically deleted in WS. This deletion includes a single gene, GTF2I, within the WS critical region. The GTF2I-ZP3 fusion transcript resulting from
the deletion is shown below the genes track. The green arrowhead shows the location of a CNV at the telomeric breakpoint inherited on the deleted
chromosome 7. The gel image shows presence of a PCR fragment amplified from the deletion junction in genomic DNA from the proband, but not in
either parental sample, indicating the deletion occurred de novo.
doi:10.1371/journal.pone.0012349.g003
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probes, one in the putative deletion (RP11-554H10) and a second
in an adjacent non-deleted region including MYCN (Figure 4B, C).
In 79% of the cells two signals from each BAC were present
indicating the cells were not deleted (Figure 4B). In the remaining
21% of cells one chromosome lacked a signal from the BAC within
the putative deleted region (Figure 4C) confirming mosaicism. We
were not able to clone a junction fragment from this proband
because of the presence of LCRs at the deletion boundaries.
However, qPCR data confirmed the deletion was at least 1.37 Mb
and contained 14 RefSeq genes.
The last group of probands with non-syndromic MCA and ID
we describe had large duplications (Figures 5 and S4). Because of
the nature of duplications cloning the end points was not feasible.
However, the identification of these large rearrangements
demonstrates the power of arrays to identify alterations not
detected by standard cytogenetics. Proband 9148 has moderate ID
plus dysmorphic features. She has a 17.16 Mb duplication at
2(p22.1p16.1) involving at least 74 RefSeq genes. Proband 8464
also has moderate ID and a range of other anomalies (Table S4).
He has a 7.82 Mb duplication at 16(p12.2p11.2) involving 61
RefSeq genes. For these two cases we used FISH to demonstrate
that the rearrangements were tandem duplications (data not
shown). The final proband studied, 8293, has mild ID and a large
number of other clinical signs (Table S4). He has a 1.1Mb
duplication at 1(p36.11p35.3) involving at least 25 RefSeq genes.
Large rearrangements of this region have not been previously
reported, although the telomeric breakpoint is located in a CNV
present in the general population [39].
The duplications in 9148 and 8464 have one or both
breakpoints, respectively, in LCRs. The duplication in 8464
involves LCRs that are involved in mediating, or located near to,
the boundaries of a reciprocal microdeletion syndrome with
variable breakpoints [40]. Therefore, this duplication is likely to
represent a new genomic syndrome. Confirmation will require
ascertainment of additional individuals with similar duplications
and phenotypes.
The three duplications described above contain large numbers
of genes including many known to be important in development.
As a consequence, we believe that these duplications are very likely
responsible for the ID/MCA observed in the probands. However,
confirmation of pathogenicity must await identification of
additional cases with similar duplications.
Discussion
High resolution cytogenetic analyses have been used clinically
for many years and while enormously powerful; their resolution is
usually restricted to detecting deletions and duplications of several
megabases. Recently, several new technologies to examine genome
copy number have been described and now are being used
clinically. These include aCGH utilizing BAC clones and
oligonucleotide arrays with dense whole genome coverage. In this
report we describe the results from high density SNP array
analyses of 38 individuals with unusual 7q11.23 alterations or with
non-syndromic ID/DD and/or MCA. Consistent with other
studies that have used this or similar technologies we found several
individuals with large genome rearrangements that have not been
described in the general population.
The use of microarrays yielded several benefits. In many cases
the resolution of known cytogenetic abnormalities could be refined
greatly and in several cases we were able to rapidly clone and
characterize the deletion breakpoints. We found that, even in
individuals previously characterized with high-resolution karyo-
Figure 4. Identification of LCR mediated mosaic deletion using SNP arrays. (A) Chromosome features for the region of interest in proband
8772 are shown versus the physical position in Mb on the February 2009 human genome assembly. Red box on ideogram denotes region of detail.
LCRs, structural variants, the FISH probes used and the location of qPCR assays also are shown. The copy number section shows the data for the SNP
arrays (black dots) and qPCR (Xs) assays. The tick marks represent 2 copies (red) and 1.5 copies (blue). Note the paucity of SNPs in the LCRs and that
the putative deletion ends in the LCRs. (B, C) metaphase FISH using BAC probe RP11-554H10 (green) and a BAC probe (red) located within MYCN at
2p24.3, which is distal to the region of interest. (B) FISH analyses show images from a normal cell from 8872. (C) FISH analyses showing a cell with one
chromosome deleted for BAC RP11-554H10. (B1, B2, C1, C2) Detailed views of both chromosomes 2 in each cell. Note absence of hybridization to
RP11-554H10 in C2.
doi:10.1371/journal.pone.0012349.g004
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rearrangements were present. While this study is not the first to
use this or similar technologies to characterize genome rearrange-
ments, it is unique in that we characterized the extent of the
deletions to very high resolution by cloning and sequencing several
breakpoints.
These studies lead to important findings that need to be
considered when interpreting data from arrays. The significance of
CNVs in determining clinical phenotypes is difficult to determine.
However they are often involved in the creation of genomic
rearrangements, both benign and pathologic (see ref [14] for
recent review). The consequence of these rearrangements with
respect to their clinical relevance usually relies on knowledge of
what constitutes normal verses pathogenic variation. Databases of
structural variants and abnormalities [27,29] are often used to
determine whether an observed copy number change is potentially
pathogenic. CNVs reported to be present in the general
population are typically considered unlikely to be the causative
mutation in individuals with abnormal phenotypes. However, the
validity of this approach depends on the accuracy of the data in
the databases. Many of the CNVs in public databases were
computationally identified from genomic data and the alterations
Figure 5. Duplications in probands with ID/MCA. Chromosome features for the regions of interest are shown versus physical position in Mb on
the February 2009 human genome assembly. Red boxes on ideograms denote regions of detail. LCR and structural variant tracks were adapted from
the UCSC Genome Browser. CNV and structural variation tracks show type and position of variants as reported in the general population: red, loss;
green, gain; blue, both; grey, inversion. SNP copy number charts were derived from our microarray (black dots) and qPCR (Xs) results. Heat maps
indicate p-values of observed copy number change for individual SNPs calculated using Partek Genomics Suite 6.3. Shading from blue to red
represents probability from 0.0–1.0 of normal copy number. (A) Dup(1)(p36.11p35.3) in proband 8293. (B) De novo dup(2)(p22.1-2p16.1) in proband
9148. (C) De novo LCR-mediated dup(16)(p12.2-16p11.2) in proband 8464. (D1) and (D2) show detailed views of LCR architecture at the16p12.2 and
16p11.2 breakpoints, respectively. Directly oriented copies of UCSC segmental duplication 11963 are boxed in black.
doi:10.1371/journal.pone.0012349.g005
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lead to CNVs being considered to be normal population variants
when in fact they cause clinically relevant phenotypes. We
identified one such CNV, variation 3686 in the Database of
Genomic Variants [27] at 7q11.23. Variation 3686 includes the
complete coding region of GTF2I and several exons of GTF2IRD1.
This CNV was reported to be present in 47 of 270 HapMap
samples analyzed using BAC aCGH, but was not detected in the
same samples when they were analyzed using 500K SNP
microarrays [41]. Given that this deletion includes GTF2I,
haploinsufficiency of which is pathogenic [24,42], we believe that
Variation 3686 is an artifact of the CGH array and/or the
computational methods used to define/merge CNVs. The case of
proband 9152 who has a CNV in this region provides a cautionary
example of conflicts that may arise when using publicly available
CNV data for interpretation of CNV data in a clinical setting.
Two of the chromosome rearrangements we identified here,
mosaic del(2)(p11.2p11.2) and dup(16)(p12.2p11.2), are associated
with LCRs. Both of these regions have been considered candidate
loci for genome rearrangements in unexplained ID based on their
segmental duplication architecture [43]. The 16p12.2-16p11.2
duplication discovered in proband 8464 is the reciprocal
duplication of a recently described deletion disorder [39] and
should be considered a putative genomic disorder pending
identification of further cases with common breakpoints. Other
duplications of 16p11-16p12 have been reported but not
examined beyond the cytogenetic level [39,40]. Identification of
additional individuals with del(2)(p11.2p11.2) will be required to
establish whether this rearrangement is in fact a recurrent finding
in cases of non-syndromic MCA/ID.
Structural polymorphisms including deletions, duplications, and
inversions are common in the general population and occur
throughout the genome [3,27,41,44–47]. It has been estimated
that ,12% of the human genome is likely to be copy number
variable in the general population [48]. Although most structural
variants do not appear to cause overt effects on phenotype, it is
possible that some may predispose to pathogenic chromosome
rearrangements. For instance, individuals carrying a common
inversion polymorphism of the WS critical region [49] or copy
number polymorphisms in the flanking LCRs [50] have increased
likelihood of offspring with WS [51]. There are structural variants
in the general population that co-localize with 11 of 21 (52%) of
the breakpoints we have defined in this study. An elegant
discussion of the importance of structural variation of the genome
and the difficulties in CNV data interpretation has recently been
published [52].
It is not unusual to discover that individuals with ID phenotypes
have more than one significant genomic rearrangement, as seen in
probands 9101 and 9164. In addition, large deletions and
duplications are frequently complex in nature. Proband 9101,
who carries a large deletion and an inversion that shared one of
the deletion breakpoints, highlights this point. The inversion
would not have been discovered had we not cloned the breakpoint,
because there was no reason to suspect this defect. Further, the
inversion inactivated an additional gene, which could be
important for interpreting genotype-phenotype relations. The
frequency of such complex rearrangements in individuals with
deletions is currently unknown. In the very near future whole
genome sequencing will become feasible from a cost perspective
and such rearrangements will be readily detected. Until that time,
care needs to be taken in interpreting CNV data, particularly using
relatively low resolution methods.
Increasing the percentage of ID/MCA cases that can be rapidly
and correctly diagnosed is a major goal for clinical genetics. We
successfully used SNP microarrays to discover novel genome
rearrangements in 6/31 (19%) of probands with non-syndromic
ID/DD or MCA. Further, the ascertainment of two cases with
unsuspected multiple chromosome rearrangements in a relatively
small cohort suggests that this phenomenon may not be rare. The
identification of additional rearrangements in some individuals on
cloning the breakpoints, which were not detected by copy number
measurements, indicates that care should be taken in genotype-
phenotype correlations in the absence of sequence data. This
concern will no doubt be eliminated as whole genome sequencing
enters the clinic, increasing our understanding of the dynamics
involved in sporadic chromosome rearrangements.
Supporting Information
Table S1 Primers used for amplification of deletion junctions
and sequences flanking breakpoints.
Found at: doi:10.1371/journal.pone.0012349.s001 (0.05 MB
PDF)
Table S2 Primer sequences for qPCR assays.
Found at: doi:10.1371/journal.pone.0012349.s002 (0.08 MB
PDF)
Table S3 Chromosome rearrangements characterized by SNP
microarray.
Found at: doi:10.1371/journal.pone.0012349.s003 (0.02 MB
PDF)
Table S4 Clinical findings in probands with genome
rearrangements.
Found at: doi:10.1371/journal.pone.0012349.s004 (0.01 MB
PDF)
Table S5 List of statistically identified CNVs.
Found at: doi:10.1371/journal.pone.0012349.s005 (0.08 MB
PDF)
Figure S1 Schematic representation of staggered primer method
for identifying deletion junctions. Gene and LCR tracks are from
the UCSC Genome Browser [26]. (A) SNP copy number results
from 250K StyI array showing 503 kb deletion in proband 9061.
Black dots on copy number track represent raw copy number,
magenta triangles show copy number inferred by median
smoothing using a 7 SNP window, and red line indicates a cutoff
of 1.5 for defining deleted SNPs. (B) Detail of relative locations of
PCR primers tested. The 4.1 kb fragment represents the junction
fragment amplified and sequenced in this proband.
Found at: doi:10.1371/journal.pone.0012349.s006 (0.16 MB TIF)
Figure S2 Schematic diagrams detailing genes deleted in
probands. The red box on each diagram represents the affected
region. The LCR-mediated, typical WS deleted region is shown in
yellow on A and B. The RefSeq and sno/miRNA genes deleted for
each proband are shown. Diagrams were adapted from UCSC
Genome Browser [26]. (A,B) Genes affected on chromosome 7
including all or part of the WS typical region for probands (A)
8399, (B) 9164, 9061, 9101 and 9152. (C) Genes impacted by the
deletion (red) and inversion (grey) on chromosome 5 of proband
9101. Note the disruption of CDH10 at the inversion junction. (D)
Deletion on chromosome 1 of proband 9164 impacting 10 RefSeq
genes.
Found at: doi:10.1371/journal.pone.0012349.s007 (0.41 MB TIF)
Figure S3 Schematic diagrams showing genes affected by
deletions in three probands with ID/MCA. Schematic diagrams
of the affected chromosomes showing the location of the
duplication on the February 2009 map. The green bars show
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9152, 8771) discussed in the text.
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Figure S4 Schematic diagrams showing genes affected by
duplications in three probands with ID/MCA. Schematic
diagrams of the affected chromosomes showing the location of
the duplication on the February 2009 map. The green bars show
the location of the duplicated region for the three probands (8293,
9148, 8464) discussed in the text.
Found at: doi:10.1371/journal.pone.0012349.s009 (0.28 MB TIF)
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